Logomix Biotechnology, Inc.
PrivateLast Round
Series A
Jul 30, 2025
Total Funding Raised
$24.25M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Logomix Biotechnology, Inc. operates in Healthcare & Life Sciences and is based in San Carlos, California. Its latest recorded funding round was a Series A round in July 2025.
Logomix Biotechnology, Inc. is a synthetic biology company that develops a proprietary Geno-Writing™ platform for large-scale, precise genome engineering in human induced pluripotent stem cells (iPSCs) to support cell therapy and regenerative medicine.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clean Manufacturing, Sustainable Materials
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Logomix Biotechnology, Inc. Comparables
Compare Logomix Biotechnology, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Bacchus Bio innovation Co., Ltd. | 77% | |
| Constructive Bio | 70% | |
| Ginkgo Bioworks | 70% |
For institutional investors. Book with your work email.
Logomix Biotechnology, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jul 30, 2025 | ||||
| Grant | May 1, 2024 | ||||
| Seed | Feb 8, 2023 |
For institutional investors. Book with your work email.
Logomix Biotechnology, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| GLOBIS Capital Partners | Series A |
| JAFCO Group Co., Ltd. | Series A, Seed |
| MIRAISOZO INVESTMENTS Inc. | Series A |
| Angel Bridge | Series A, Seed |
| ITOCHU Technology Ventures | Series A |
| New Energy and Industrial Technology Development Organization | Grant |
| Norinchukin Capital Co., Ltd. | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 89% MoM.
- May 26, 2026
Joint research in regenerative medicine and cell therapy announced.
For institutional investors. Book with your work email.
Logomix Biotechnology, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Logomix Biotechnology, Inc.'s valuation, stock price, and market status.
Is Logomix Biotechnology, Inc. a public or private company?
Logomix Biotechnology, Inc. is a private company.
What is the current stock price of Logomix Biotechnology, Inc.?
Logomix Biotechnology, Inc. is a private company, so its shares have no public market price. Caplight tracks Logomix Biotechnology, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Logomix Biotechnology, Inc. worth (valuation)?
Valuation information for Logomix Biotechnology, Inc. is not publicly available.
Can I buy Logomix Biotechnology, Inc. stock?
Logomix Biotechnology, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Logomix Biotechnology, Inc.'s last funding round?
Logomix Biotechnology, Inc.'s most recent funding round was Series A on July 30, 2025.
Who are the main investors in Logomix Biotechnology, Inc.?
Key investors in Logomix Biotechnology, Inc. include Angel Bridge.
Will Logomix Biotechnology, Inc. IPO soon?
No public IPO plans have been announced for Logomix Biotechnology, Inc..
How can I track Logomix Biotechnology, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Logomix Biotechnology, Inc.'s shares on secondary markets.